A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Financial Summary
| Share Statistics | AEON | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $13.6 | $223.5 | 9% |
|
| Shares Out (Mil) | 50.5 | 53.4 | 48% |
|
| Institutional Ownership | 59.7% | 92.9% | 39% |
|
| Float (Mil) | 24.0 | 40.4 | 31% |
|
| Beta | 0.69 | 0.96 | 40% |
|
| Avg Daily Volume (000s) | 419 | 463 | 56% |
|
| Price Change (52-week) |
(67.7%) | 45.9% | 13% |
|
| Growth | AEON | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (3.6%) | (10.1%) | 35% |
|
| EPS (5yr) | 62.7% | 15.8% | 96 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (71.2%) | (15.7%) | 2% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 3 | 3 | |
| Current EPS | ($0.083) | ($0.453) | ($0.253) | |
| Month Ago EPS | ($0.067) | ($0.455) | ($0.270) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.270) | ($1.050) | na | |
| Year/Year Chg | 260.9% | (88.5%) | (96.7%) | |
| Financials | AEON | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($55) | ($44) | 15% |
|
| EPS (TTM) | ($1.887) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($14) | ($33) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $13 | $173 | 9% |
|
| Valuation | AEON | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.08 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AEON | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (621.7%) | (47.0%) | 0% |
|
| ROE | 350.0% | (52.7%) | 99% |
|
| Liabilities to Assets | 359.9% | 29.6% | 100% |
|
| F-Score | 2 | 2 | 7% |
|
AEON Biopharma, Inc. did not pass any screens on 11/2/2026.
